Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression
An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The biotech isn’t abandoning the asset just yet, but even if …